title: Current adjuvant therapeutic approaches for pancreatic cancer.
abstract: Pancreatic cancer continues to be the fourth leading cause of death despite advancements in surgical and adjuvant therapeutic approaches. In the present review, the current cytotoxic therapeutic approaches and advanced targeted therapies are objectively discussed with consideration to the current literature.
authors.affiliation: Department of Basic Oncology, Cancer Institute, Hacettepe University, Ankara, Turkey.
authors.forename: Fusun
authors.initials: F
authors.lastname: Ozmen
authors.forename: Tevfik Tolga
authors.initials: TT
authors.lastname: Şahin
authors.forename: M Mahir
authors.initials: MM
authors.lastname: Ozmen
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology; D000068258:Bevacizumab / Q000494:pharmacology*; D000068818:Cetuximab / Q000494:pharmacology*; D017024:Chemotherapy, Adjuvant / Q000379:methods*; D000069347:Erlotinib Hydrochloride / Q000494:pharmacology*; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods; D009367:Neoplasm Staging; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D000068258:Bevacizumab; D000069347:Erlotinib Hydrochloride; D000068818:Cetuximab